Table 2. Summary of included studies and participants’ characteristic.

Health professionals targeted	Breast and ovarian cancer intervention (n = 20)		Colorectal and endometrial cancer intervention (n = 5)
	Number of studies/Total (%)	References	Number of studies/Total (%)	References
Genetic counsellors	12/20 (60%)	[29, 31, 33, 35, 37, 38, 41, 43, 46, 48, 53, 54]	3/5 (60%)	[42, 44, 47]
Medical oncologists	13/20 (65%)	[29, 30–33, 37, 43, 45, 48, 51, 53–55]	2/5 (40%)	[42, 47]
Gynaecology oncologists	9/20 (45%)	[29, 33, 35, 38, 39, 45, 46, 53, 55]	NA
Clinical nurse specialists	5/20 (25%)	[29, 30, 33, 37, 55]	3/5 (60%)	[39, 41, 42]
Advanced nurse practitioners	3/20 (15%)	[35, 38, 39]	NA
Clinical geneticists	4/20 (20%)	[37, 43, 48]	2/5 (40%)	[42, 47]
Resident or fellow or trainee	2/20 (10%)	[35, 37]
Other	1/20 (5%)	[38, 45]
Pathologists	NA		5/5 (100%)	[39, 41, 42, 44, 47]
Surgeons	NA		4/5 (80%)	[41, 42, 44, 47]
Location all studies n = 27
North American and Canada	12/27 (44%)	[34–39, 41, 44–47, 54]
United Kingdom	8/27 (30%)	[29, 30, 31, 32, 40, 50, 51, 52]
Australia	5/27 (18%)	[33, 48, 43, 42, 49]
Europe	2/27 (7%)	[53, 55]
System setting n = 25
Single site urban hospitals	16/25 (59%)	[29, 30, 33, 36, 37, 39, 40, 43, 46, 47, 51, 52, 55]
Large multi-site urban and regional hospital	6/25 (24%)	[34, 35, 38, 41, 44, 53]
State wide systems	3/25 (12%)	[43, 45, 54]
Unspecified health system	1/25 (4%)	[42]
Study Design n = 27
Cohort	11/27 (40%)	[34, 36, 37, 42–44, 46, 47, 54, 55]
Case series	14/27 (51%)	[29–33, 35, 38, 39–41, 48, 51–53]
Qualitative	2/27 (7%)	[49, 50]